Among the metabotropic glutamate (mGlu) receptors, mGlu2, an inhibitory presynaptic autoreceptor, has emerged as a novel therapeutic target for the treatment of psychiatric disorders including schizophrenia, depression and anxiety, which are characterized by glutamatergic dysfunction (Marek et al. This evidence concerns the gene GRM2 and schizophrenia.